Roger Longman, Managing Partner with Windhover Information, began the plenary session with a one-man show that was a tour de force of recent dealings in the pharma-biotech sector.
He began with one alarming fact drawn from Windhover’s Strategic Transactions Database: Failure rates for Phase III drug development programs are now running three-in-four, a startling 50% increase Read more »
Suddenly everything changed in 2006. Where pharmaceutical companies led the dance with the biotech sector with in-licensing and merger and acquisitions focused on mid- to late-stage projects, sometime last year all that changed with an abrupt shift of focus upstream toward early stage deals.
The motivations driving this change were the subject of an intensive 90-minute Read more »
He is simply “The Vaughn,” a man who needs no further introduction for anyone cutting a deal in the heady mega dollar world where Big Pharma and Biotech meet.
Over half of the 2,250 delegates at BIO-Europe 2007 attended the opening plenary session on Monday and had no trouble spotting the moderator for Read more »
BIO-Europe Spring 2008 in Madrid April 7-9 aims to be the perfect follow-on to your productive experience here in Hamburg.
The springtime counterpart to the flagship BIO-Europe conference, the Madrid conference edition keeps the deal-making momentum moving,bringing companies from across the biotech value chain into a unique forum tailored for partnering.
In collaboration with the Biotechnology Industry Read more »
The success of BIO-Europe among key pharma-biotech players is the powerful mix of “virtual” online collaboration with a physical event.
While the exhibition and intensive conference program create a vibrant ambiance at BIO-Europe, the meetings among partners is the true focus of this pure-play partnering event.
A novel Web-based partnering system enables delegates to screen thousands of Read more »
Evotec AG accelerated powerfully in October announcing positive results from its Phase II Trial of EVT 201, the acquisition Renovis, and a renewed focus on novel drug candidates to treat disorders of the central nervous system. Beyond proprietary programs, Evotec is actively seeking partners for contract research with an emphasis on opportunities for its fragment-based Read more »
At BIO-Europe, DNA sequencing and bioinformatics specialists GATC will launch a commercial human genome sequencing service, with the capability to sequence up to 100 genomes by the end of 2010.
This ambitious target will be achieved by forming collaborative partnerships with leading pharmaceutical, pharmacogenomics and diagnostics companies, as well as leading research institutes.
These partners Read more »
A magnificent setting and an impressive turnout of over 1,000 delegates made for an exciting evening of networking, presentations and casual conversation to kick off BIO-Europe 2007 Sunday evening at Hamburg’s elegant Rathaus (Town Hall).
Political and industry dignitaries representing Life Science Nord welcomed BIO-Europe participants from 40 countries to the festivities.
Dr. Kathrin Adlkoffer, Managing Director Read more »
Newsletter